Sotera Health price target lowered to $16 from $17 at Barclays

Barclays analyst Luke Sergott lowered the firm’s price target on Sotera Health (SHC) to $16 from $17 and keeps an Overweight rating on the shares following the earnings report. The firm sees a consistent recovery in the business continuing through the year. Sotera’s guidance was below estimates, driven by currency, which should be looked through by investors, the analyst tells investors in a research note.